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EMERGING MARKET FOR BIOSIMILARS: STATE
LEGISLATION SHOULD RECONCILE BIOSIMILAR
SUBSTITUTION LAWS WITH EXISTING LAWS ON
GENERIC SUBSTITUTION
Brian F. King*
INTRODUCTION
The pharmaceutical industry flourished throughout much of past
two decades, creating a vast wealth of scientific knowledge and
revolutionary treatments. Because of these life-saving therapies, people
are living longer. Consequently, our aging population requires more
medications than ever before. Who will bear the cost? Insurance
companies? The government? Regardless of who picks up the tab, the
true cost of healthcare will rest squarely upon the shoulders of the
American people.
The cost of healthcare has become a tremendous concern that
cannot be ignored. The US continues to spend a greater percentage of its
wealth on healthcare than any other industrialized nation. “In 2012, the
US spent an average of $8,915 per person on health care, reaching a total
of $2.8 trillion.”1 Much of this was spent on medications and a growing
proportion was spent on a new class of therapies called biologics. As the
market for biologics continues to grow, it becomes increasingly important
for state legislation to balance the competing interests of scientific
innovation and public access.
This article is intended to explore the growing market of
biosimilars and to provide insight into the developing body of law. It
should appeal to the interest of healthcare providers and those who have a
special interest in the future of the pharmaceutical industry.
After
considering the recent developments in State and Federal law and the
arguments for and against provisions of state legislation, this paper takes
the position that, while some additional measures should be considered in
* J.D. Candidate, DePaul University College of Law (2017); Pharm.D., RPH. Brian King is current
student at DePaul University College of law in Chicago. Dr. King holds a PharmD from
Purdue University and is a practicing Pharmacist in the Chicago area. He has a special
interest in drug and biotech patents.
1
Katherine Wilson, Health Care Costs 101: Slow Growth Persists, California HealthCare
Foundation, available at, http://www.chcf.org/publications/2014/07/health-care-costs-101.
(July 2014).
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state legislation to address the variability and unpredictability of biologics
and biosimilars, state legislation that erects unnecessary barriers to the
utilization of biosimilars will increase the cost of healthcare and will stifle
innovation.
Section I provides a background to biologics, with a focus on their
cost and complexity. Section II provides a brief overview of the FDA
drug approval process, and an explanation of the biologic and biosimilar
approval processes. Section III discusses the laws for generic substitution
generally, with a focus on the status of Federal law as well as recent
developments of State law that have affected the market for biosimilars.
Section IV introduces the developing role of state laws and provides a
survey of statements from various interest groups that depict the key
arguments for and against various components of state legislation. Section
V presents implications associated with the new market for biosimilars
concerning the provision of healthcare and the development of new
products within the pharmaceutical industry. After considering the costs
and benefits of biosimilars, Section VI provides a variety of
recommendations for healthcare providers, policy-makers, and
stakeholders in the pharmaceutical industry as the market for biosimilars
continues to develop and the accompanying body of law attempts to
reconcile the public’s need for access to high quality biologics and the
pharmaceutical industry’s incentive to invest in a unpredictable market.
II. BACKGROUND OF BIOLOGICS
Each year, the government agency Medicare Payment Advisory
Commission (“MedPAC”) Biological products, like other drugs, are used
for the treatment, prevention, or cure of disease in humans. In contrast to
traditional chemically synthesized small molecular weight drugs, which
have a well-defined structure and can be easily characterized, biological
products are generally derived from living materials, which are complex in
structure and usually not fully characterized.2
Biologic drugs were first developed in the 1980s and were
considered so specialized that making “generic” versions was thought to
be nearly impossible. But over the past 30 years, science has advanced
2
FDA, Biosimilars: Frequently Asked Questions About Therapeutic Biological Products, at,
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/%.
20HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologic
Applications/ucm113522.htm (hereinafter FDA).
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dramatically, and as patents on existing biologics began to expire, drug
companies sought FDA approval for close copies of patented biologics.
As expected, companies with the original patents initially resisted,
insisting that their products were so complex that it was impossible to
copy, but with the passing of time, that argument has lost some of its
steam.3
The FDA and Section 351 of the Public Health Service (PHS) Act
define a biological product as a “virus, therapeutic serum, toxin, antitoxin,
vaccine, blood, blood component or derivative, allergenic product, or
analogous product … applicable to the prevention, treatment, or cure of a
disease or condition of human beings.”4
A.Complexity of Biologics
“Biologic medicines are much more complex than traditional
chemically synthesized drugs. Biologics are manufactured from living
organisms by programming cell lines to produce desired therapeutic
substances consisting of large, complex molecules.”5 Because of their
complexity, it is much more difficult to replicate biologics than traditional
drugs in the manufacturing process.6 Even the smallest change in the
manufacturing process can have profound effects on the predictability of a
product’s efficacy and safety.7 Because of this, it is practically impossible
to produce a generic version of a biologic that is truly identical.8
“However, once patents expire for the existing brand-name biologic drugs,
“biosimilar” medicines can be produced.”9
Unlike generic drugs,
biosimilars are not therapeutic equivalents of a reference biologic. Nor are
they required to seek approval for the all of the indications or dosage
forms of a reference biologic.
Because of the potential differences between biosimilars and the
reference product, biosimilars are not automatically interchangeable.
3
Sabrina Travernise & Andrew Pollack, F.D.A. Approves Zarxio, Its First Biosimilar Drug, NEW YORK
TIMES (Mar. 6, 2015).
4
FDA, Supra note 2.
5
Richard Cauchi, National Conference of State Legislatures, State Laws and Legislation Related to
Biologic Medications and Substitution of Biosimilars. (Sep. 10, 2015), available at
http://www.ncsl.org/research/health/state-laws-and-legislation-related-to-biologic-medications-andsubstitution-of-biosimilars.aspx.
6
Id.
7
Id.
8
Id.
9
Id.
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There are a number of considerations that must be addressed before a
biosimilar can be classified as interchangeable. The FDA employs a
“totality of evidence” approach regarding data for approval of a biosimilar,
meaning that a variety of sources of data can be used for biosimilar
approval. Once a biosimilar is approved, its ability to be prescribed and
dispensed will be dictated by its classification as either “interchangeable”
or simply “biosimilar.” Generally, products that are interchangeable can
be substituted for the reference product, while biosimilars, without more,
cannot.
B. Cost of Biologics
In 2010, spending on biologics in the U.S. reached an astounding
$67 billion, representing nearly 30 percent of the overall prescription drug
market, and displaying a much steeper growth rate than traditional drugs.10
In 2013, total drug expenditure in the United States was approximately
$326 billion.11 Of the top 15 drugs, 8 were biologics, representing 9% of
total drug expenditure.12 In fact, biologic and specialty pharmaceuticals
are the fastest growing pharmaceutical expense in the US.13 On average,
biologic drugs are 22 times more expensive than traditional brand name
drugs.14
Numerous strategies have been considered to address the growing
costs of biologic medications. One strategy of cost containment has been
the introduction of competing products known as biosimilars.15
Biosimilars have the potential to provide considerable cost savings. The
US Congressional Budget Office estimated that price competition from
biosimilars would reduce total expenditures on biologics in the United
States by $25 billion over a 10-year period, with a decrease in federal

10
Michael Ollove, More States Demand Notification to Use Biosimilar Drugs (Mar. 30, 2015),
http://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2015/3/30/more-states-demandnotification-to-use-biosimilar-drugs
11
Univ. of Ill. at Chicago. Coll. of Pharmacy, What is the Status of Biosimilars in the United States? (Nov.,
2014), available at http://dig.pharm.uic.edu/faq/2014/Nov/faq1.aspx. (hereinafter Univ. of Ill.).
12
Id.
13
James G. Stevenson, Preparing for Biosimilars: Scientific, Regulatory, and Practice Management Issues
for
Pharmacists
(Dec.
12,
2012)
(live
webcast)
available
at
http://www.ashpadvantagemedia.com/downloads/handout_biosimilars.pdf.
14
Anthony D. So & Samuel L. Katz, Biologics Boondoggle, NEW YORK TIMES, Mar. 7, 2010.
15

Steven D. Lucio, Evaluating Biosimilars for Formulary Inclusion, PHARMACY PURCHASING &
at http://www.pppmag.com/article_print.php?articleid=1591.

PRODUCTS, available
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government spending of nearly $6 billion.16 The American Consumer
Institute Center for Citizen Research estimates savings of $250 billion in
the US over the next 10 years from just 11 biosimilar products.17
Therefore, there will be significant pressure in the coming years to utilize
biosimilars to control health care costs.
III. THE APPROVAL PROCESS OF GENERIC DRUGS AND
BIOSIMILARS
Despite the perceived benefits of the readmission penalty, the
Program has received significant criticism. The Food and Drug
Administration (“FDA”) regulates traditional drugs under the Food Drug
and Cosmetic Act (“FD&C Act”). In contrast, biologics are regulated
under the Public Health Service (“PHS”) Act. Compared to the FD&C
Act, the PHS Act gives the FDA greater regulatory control over the
manufacturing processes that are uniquely important in the production of
biologics.
The paragraphs that follow provide insight into the framework of
the approval pathways for traditional drugs and biologic drugs, as well as a
brief overview and comparison of the approval processes for generic and
biosimilar counterparts respectively.
A. The Food, Drug, and Cosmetic Act and Hatch-Waxman
Amendments Regulate the Abbreviated Pathway for Traditional Drugs
The FD&C Act defines an abbreviated new drug application
process through which generic manufacturers can obtain approval once
adequate information is offered to demonstrate bioequivalence with the
reference product. Generally, these applications do not require a sponsor
to conduct clinical trials. However, additional clinically related data may
be required for certain products, such as immunogenicity data. For
biologics, the PHS Act allows approvals via 351(a) BLA application when
a sponsor demonstrates the safety, purity, and potency of an
investigational product through clinical studies. The new 351(k) pathway
16
S.1695. Biologics Price Competition and Innovation Act of 2007, CONGRESSIONAL BUDGET OFFICE
(June 25, 2008).
17
Lucio, supra note 11.
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will allow for an abbreviated approval of a biosimilar. However, unlike
ANDA applications, the biosimilar pathway requires at least one clinical
study to support product approval.
B. The Public Heath Service Act and Biologics Price Competition
and Innovation Act Regulate the Abbreviated Pathway for Biologics
To help reduce the cost of biologics, the Biologics Price
Competition and Innovation (BPCI) Act was implemented as part of the
Affordable Care Act (ACA) to allow for a streamlined approval process
for biologics that are similar to existing agents, in the expectation of
reducing the cost of development of these agents.18 Unlike small molecule
drugs, which are approved under the FD&C Act, the FDA approves most
biologics under section 351 of the PHS Act. Compared to the FD&C Act,
the PHS Act gives the FDA greater regulatory control over the
manufacturing processes that are especially critical in the production of
biologics. Just as the 1984 Hatch-Waxman amendments established the
abbreviated new drug application (ANDA) for generic medications, the
BPCI Act created a licensure pathway in which a follow-on product could
rely on existing scientific knowledge about the originator’s reference
biologic.19
While the intent of the BPCI Act is similar to that of the HatchWaxman Amendments, the approval processes for small molecule drugs
and biologics differ substantially. For example, both innovator and
generic versions of traditional drugs are approved under the FD&C Act,
whereas biologics are approved under the PHS Act.20 While generic
approvals primarily consist of bioequivalence studies only, biosimilar
approvals require at least one clinical trial be conducted to demonstrate it
is “highly similar” to its reference biologic.21
The Patient Protection and Affordable Care Act (“PPACA”)
created an approval pathway for less expensive generic versions of
biologic drugs, known as biosimilars, or follow-on biologics. However,
new state legislation that could greatly limit the savings from biosimilars
has sparked a debate similar to the one that followed the passage of
18

Univ. of Ill., supra note 8.
Lucio, supra note 11.
Preparing
for
Biosimilars,
Novation
(Nov.
2011),
available
at
https://www.novationco.com/media/newsreleases/attachments/preparing_for_biosimilars.pdf(hereinafter
Preparing for Biosimilars).
21
Id.
19
20
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legislation that encouraged the development of traditional generic drugs.22
The enactment of BPCI Act reflected an attempt to balance the interests of
pharmaceutical manufacturers in recovering the costs of innovation and
drug development with the need for patients to have access to more
affordable versions of currently marketed treatments.23
Under the BPCI Act, a biological product may be classified as
“biosimilar” if data show that the product is “highly similar” to or
“interchangeable” with an already-approved reference biological
product.24 “Biosimilarity” means that “the biological product is highly
similar to the reference product notwithstanding minor differences in
clinically inactive components, and that there are no clinically meaningful
differences between the biological product and the reference product in
terms of the safety, purity, and potency of the product.”25
“Interchangeability” means that the biosimilar must produce the same
expected clinical results as the reference biologic, and if the biosimilar is
meant to be given more than once, it should not have a greater risk of
diminished efficacy or safety concerns than the reference biologic.26 If the
biosimilar is interchangeable, it may be substituted with the reference
biologic without intervention by the prescriber.27
Given the abbreviated nature of the approval process, biosimilars
are expected to cost less than the original reference product.28 However,
whereas the ANDA process requires no additional clinical trial
information, the complexity of biologic medications necessitates that a
biosimilar application includes data substantiating that it “does not differ

22
Leigh Purvis, A Sense of Déjà Vu: The Debate Surrounding State Biosimilar Substitution Laws, AARP
Public
Policy
Institute
(Sept.
2014),
available
at
http://www.aarp.org/content/dam/aarp/research/public_policy_institute/health/2014/the-debatesurrounding-state-biosimilar-substitution-laws-AARP-ppi-health.pdf.
23
Lucio, supra note 11.
24
FDA,
Biosimilars,
(Mar.
6,
2015),
at
http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplic
ations/therapeuticbiologicapplications/biosimilars/default.htm.
25
FDA, Christl Leah, FDA’s Overview of the Regulatory Guidance for the Development and Approval of
Biosimilar
Products
in
the
US
(Jan.
2,
2015)
1,
6
at
http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApprove
d/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM428732.pdf.
26
Id. at 8.
27
Id.
28
Ramon
Hernandez,
Biosimilar
Products,
FDA
(June
20,
2013)
at
http://www.piapr.org/clientuploads/11th%20PIAFDA%20RegConf%20(June%2020,%202013)/PP/1%20Biosimilar%20Products%20by%20R.%20Hernand
ez.pdf.
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in a clinically meaningful way from the reference product in terms of
safety, purity, or potency.”29
Biological products are a subset of drugs that are licensed under
section 351 of the PHS Act.30
Because of the complexity of
manufacturing and characterizing a biologic product, the PHS Act
provides for a system of controls over all aspects of the manufacturing
process.31 It is difficult to characterize and identify the clinically active
components of a complex biological product, thus such products are often
defined by their manufacturing processes. “Since there is a significant
difference in how biological products are made, the production is
monitored by the agency during every stage of development to ensure the
final product turns out as expected.”32
The PHS Act allows approval of biologics via a 351(a) BLA
application when a sponsor demonstrates the safety, purity, and potency of
an investigational product through clinical studies.33 Prior to the creation
of the biosimilar pathway under the BPCI Act, otherwise known as a
351(k) application, the 351(a) BLA application was the only biologic
approval mechanism available.34 The new 351(k) pathway is significant
in that it allows for an abbreviated approval of a biosimilar without
requiring extensive investigation and unnecessary clinical trials.35
The purpose of the 351(k) approval process is not to replicate in its
entirety the clinical development actions of the originator. Instead,
through a series of characterizations supported by pharmacokinetic,
pharmacodynamic, and immunogenicity studies, as well as targeted
clinical trial data, an applicant can prove that a product so closely
resembles the originator reference biologic that the biosimilar would be
expected to behave in a similar fashion in terms of safety and efficacy.36
The FDA describes this process as a “totality of the evidence approach,”
29
Suzanne M. Sensabaugh, Requirements For Biosimilars and Interchangeable Biological Drugs in the
United States – in Plain Language 45 DRUG INFO. J. 155, 157 (2011).
30
FDA, Biosimilars Frequently Asked Questions About Therapeutic Biological Products,
at
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/%
20HowDrugsare
DevelopedandApproved/ApprovalApplications/TherapeuticBiologic Applications/ucm113522.htm.
31
Id.
32
Id.
33
Preparing for Biosimilars, supra note 16.
34
Lucio, supra note 11.
35
Preparing for Biosimilars, supra note 16, at 3.
36
FDA, Guidance for Industry: Scientific considerations in demonstrating biosimilarity to a reference
product
(April
2015)
at
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM29112
8.pdf.
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with each phase of biosimilar approval meant to resolve any residual
uncertainty from previous steps.37
A 351(k) application must include information demonstrating that
the biological product is biosimilar to a reference product.38 The sponsor
must prove that the biosimilar utilizes the same mechanisms of action for
the proposed conditions of use, that conditions of use proposed in labeling
have been previously approved for the reference product, that it has the
same route of administration, dosage form, and strength as the reference
product, and is manufactured, processed, packed, or held in a facility that
meets standards designed to assure that the biological product continues to
be safe, pure, and potent.39
As mentioned, the PHS Act requires that a 351(k) application
include, among other things, information that demonstrates biosimilarity
based upon the “totality of evidence.” This evidence is derived from three
main sources: analytical studies demonstrating that the biological product
is “highly similar” to the reference product notwithstanding minor
differences in clinically inactive components; animal studies (including the
assessment of toxicity); and a at least one clinical study that is sufficient to
demonstrate safety, purity, and potency in one or more appropriate
conditions of use for which the reference product is licensed and for which
licensure is sought for the biosimilar product.40
The BPCI Act also authorizes the FDA to designate certain
biosimilars as “interchangeable,” meaning that a pharmacist could
dispense the product in place of the originator without the involvement of
the prescriber.41 The FDA has stated that while it has authority to grant
interchangeability status, it does not expect to make such a determination
upon initial approval of the biosimilar.42 Nevertheless, this subject has
been contested in many settings, particularly in state legislatures across the
country as will be discussed infra. Ultimately, each state’s pharmacy
practice act will determine the process for implementing interchanges and
substitutions. State laws are currently an area of active debate with regard
to issues such as physician notification, patient consent, documentation,
and record retention.
For products designated by the FDA as
37

Lucio, supra note 11, at 1.
Christl, supra note 21, at 9.
39
Id.
40
Id. at 10.
41
Sensabaugh, supra note 25, at 3.
42
FDA, Draft Guidance for industry: Biosimilars: questions and answers regarding implementation of the
Biologics
Price
Competition
and
Innovation
Act
of
2009
(May
2015)
at
http://www.fda.gov/downloads/Drugs/.../Guidances/UCM273001.pdf.
38
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interchangeable with the originator product, determining best practices for
substitution in the acute-care setting may be relatively straightforward, but
their implementation in outpatient, specialty pharmacy, and retail
environments may be much more complex.
C. Exclusivity under the Biologics Price Competition and
Innovation Act of 2009
To address the uncertainty surrounding the approval pathway of
biologics, Congress passed the Biologics Price Competition and
Innovation Act of 2009 (BPCIA) as part of health care reform under the
Patient Protection and Affordable Care Act. The BPCIA contains a 12year exclusivity period for the innovator product during which time the
FDA will not approve any “follow-on-biologic” that references the
innovator product.43 These exclusivity protections may actually be more
useful to innovators than a patent because of the high level of legal
uncertainty surrounding biologic patent law. To complicate things further,
sponsors may not even be able to submit their applications to the FDA for
at least four years after the innovator receives approval.44
Like the Hatch-Waxman act did for generic drugs, the BPCIA
created a scheme for resolving challenges of patents for innovative
biologics approved under the PHSA. This scheme is “designed to enable
the resolution of patent disputes before a biosimilar enters the market.”45
Under such a scheme, “the reference product sponsor and biosimilar
applicant privately exchange information about relevant patents and
negotiate to identify patents that will be litigated through an immediate
litigation procedure.”46
However, unlike the Hatch-Waxman Act’s patent litigation
scheme, the scheme created for biosimilars “includes no provision
preventing FDA from approving a biosimilar if the biosimilar applicant
indicates it will wait for patent expiry” before entering the market,
“provides no stay of FDA approval of a biosimilar where a patent
infringement suit has been brought,” and “provides no special incentive for
biosimilar applicants to challenge or design around innovator patents.”47
43

42 U.S.C.A. § 262(k)(7)(A) (2010).
42 U.S.C.A. § 262(k)(7)(B) (2010).
Bogaert, et al., Biosimilar regulation: important considerations and global developments,
PRACTICALLAW.COM (2011), at https://www.practicallaw.com/3-500-9862.
46
Id.
47
Id.
44
45
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IV. LAWS OF THERAPEUTIC SUBSTITUTION
The practical and legal Pharmacists are given significant
responsibility by both federal and state governments to help control drug
costs by making effective generic-substitution choices. Pharmacists are
uniquely positioned to leverage their skills and knowledge to into a valuebased therapeutic decision, tailored to a patient’s specific needs. Equally
important is a pharmacist’s unique ability to recognize when a generic
substitution is not appropriate. Pharmacists should identify opportunities
for physician consultation to achieve optimal treatment outcomes that
balance demonstrated safety and cost considerations.
The FDA has taken much of the guesswork out of evaluating
whether two drugs may be substituted for one another with publication of
the Orange Book.48 According to the FDA's Approved Drug Products
with Therapeutic Equivalence Evaluations, commonly known as The
Orange Book, drug products must demonstrate pharmaceutical
equivalence and bioequivalence to be considered therapeutic equivalents.49
Therapeutic equivalent drugs are either A-rated (meaning that there are no
known or suspected bioequivalence problems) or AB-rated (actual or
potential bioequivalence problems have been resolved with adequate in
vivo and/or in vitro evidence).50 A-rated drugs may be designated AA,
AN, AO, AP, or AT, depending on the dosage form.51 This rating is often
the basis of state-specific substitution laws. In most states, pharmacists
cannot substitute “nontherapeutic equivalent products” without first
consulting the prescriber.52 “Some states allow substitution between
products as long as state-specific criteria are met, such as having the same
active ingredient, dosage form, dose, and route of administration.”53
For a number of years, before the discussion of biosimilars, at least
14 states and Puerto Rico have required pharmacists to substitute a generic
version of the prescribed drug if all prescription requirements are met.
48
Jesse C. Vivian, Generic Substitution Laws, 33 U.S. PHARM. 30, n.6
(2008),
http://www.uspharmacist.com/content/s/44/c/9787/.
49
Electronic Orange Book: Approved Products with Therapeutic Equivalence Evaluations, 35th Edition,
available at FDA.GOV, http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm.
50
Id. at xiii.
51
Id.
52
State Regulations on Generic Substitution, 22 PHARM. LETTER/PRESCRIB.220901, n.9 (Sept. 2006).
53
Id.
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These laws are not invalidated by biosimilar substitution measures enacted
as of June 2014.54
A.
Biosimilars

Federal Regulations Concerning Interchangeability of

According to U.S.C. Section 262(k)(4) - Safety Standards For
Determining Interchangeability:
Upon review of an application submitted under this subsection or
any supplement to such application, the Secretary shall determine the
biological product to be interchangeable with the reference product if the
Secretary determines that the information submitted in the application (or
a supplement to such application) is sufficient to show that (A) the
biological product (i) is biosimilar to the reference product; and (ii) can be
expected to produce the same clinical result as the reference product in any
given patient; and (B) for a biological product that is administered more
than once to an individual, the risk in terms of safety or diminished
efficacy of alternating or switching between use of the biological product
and the reference product is not greater than the risk of using the reference
product without such alternation or switch.
B. Overview of State Legislation Concerning Interchangeability of
Biosimilars
As the FDA continues work on implementing the BPCI Act, states
have considered proposals to restrict substitution of biologic medications.
Currently, there is concern that traditional statutes regulating the
substitution of traditional generic drugs may be misapplied to new
biosimilars that are not identical to the originator. This has led many
legislatures to amend older state laws, or add new sections, to address the
medical and chemical characteristics of biologics and any future genericstyle “follow-on” biologics, biosimilars, or interchangeable biological
products.55
“In the past two years at least 31 states have considered legislation
establishing state standards for substitution of a ‘biosimilar’ prescription
54
Richard Cauchi, supra note 5. See generally NABP: 2014 Survey of Pharmacy Law, pp. 67-70. Available
at http://www.ncsl.org/documents/health/Biologics_BiosimilarsNCSLReport2015.pdf.
55
National Conference of State Legislatures, State Laws and Legislation Related to Biologic Medications
and
Substitution
of
Biosimilars
(Jan.
2015),
at
http://www.ncsl.org/documents/health/Biologics_BiosimilarsNCSLReport_ July_2014.pdf.
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product to replace an original biologic product.”56 Key features of state
legislation include: prevention by a prescriber of substitution with a
biosimilar by writing “dispense as written” or “brand medically
necessary”; consideration for substitution must first be approved as
“interchangeable” by the U.S. Food and Drug Administration; notification
of the prescriber of a substitution with a biosimilar; notification of or
consent by the patient regarding the substitution; and recordkeeping of
substituted biologics by both pharmacists and prescribers.57 States will be
required to maintain a public or web-based list of permissible
interchangeable products.58 In addition, some states require the pharmacist
to explain the cost or price of the biologic and the interchangeable
biosimilar and many provide immunity for pharmacists who make a
substitution in compliance with biologics state law.59 As of the end of
2014, eight states had enacted such statues, and a number of other states
had made unsuccessful attempts.60
Some states attempted to pass legislation that used different
approaches such as “right-to-try” legislation, proposing to allow use of
experimental drugs prior to full FDA approval and economic incentive
measures intended to expand biologic research and manufacturing in
individual states.61 Supporters of state proposals believe the ultimate
decision on substitution should be left to the patient’s prescribing
physician.
Opponents believe state proposals are restrictive and
inconsistent with forthcoming national standards, and will increase the
cost of healthcare.
V. WHAT ROLE SHOULD STATE LAWS PLAY?
Not all health policy stakeholders agree on the role of state laws in
regulating biological and biosimilar medications. The paragraphs that
follow provide an overview of some of the considerations put forth by
various interest groups that support, oppose, or criticize key features of
state legislation.
A. Arguments for State Biosimilar Legislation
56

Id.
Id.
Id.
59
Id.
60
Id. at 2.
61
Id.
57
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Biologic drug companies and some patient advocacy groups,
whose views are often closely aligned with those of the drug industry,
maintain that the FDA will develop appropriate standards for the approval
of safe biosimilar and interchangeable biologic products. However, they
also believe that additional protections are needed in state substitution
policies that will “safeguard patient safety and the primacy of the
physician-patient relationship,” and “ensure transparency and
communication between patients and their treatment care teams.”62
Proponents of state legislation argue that states must step in to
protect patients that could potentially be exposed to biosimilars without
their knowledge or consent. They argue that states should develop new
statutory protections for patients that provide physicians the authority to
decide whether interchangeable biologics are appropriate substitutions for
an originator product. Some proponents go so far as to argue that the
FDA’s approach conflicts with the constitutional protections of trade
secrets. They argue that the FDA’s approach conflicts with federal laws
designed to ensure the safety of biologics, presenting serious safety
concerns and that the duty falls to the states to enact proper legislation
requiring prior authorization from a physician, and informed consent from
the patient, before a pharmacist may substitute an biosimilar for an
innovator product.
Biologic drug companies and other state biosimilar legislation
supporters have also voiced concerns over quality and support the need for
additional safeguards in state legislation.63 For example, the trade
organization that represents biologic drug companies argues, “Even though
interchangeable biologics will be expected to produce the same clinical
result, it remains the case that patients could react differently to an
interchangeable biologic than if they were given the innovator product due
to the complex nature of biologic products and how they work in the
human body.”64
Supporters of state legislation have also raised concerns regarding
adverse events, arguing that, “everyone should know which biologic a
patient is taking so it can be used for adverse event reporting.”65
Supporters of the notification provisions, including some patient advocacy
62

Purvis, supra note 21.
Id. at 2.
64
Id.
65
Id.
63
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groups and drug manufacturers, insist these provisions protect the patientphysician relationship and allow prescribers to monitor the patient’s
experience with the biosimilar.66
According to the Institute for Patient Access (IPA), “Biological
medications differ substantially from conventional drugs and are classified
differently by the FDA; as a result, laws and regulations developed for
conventional drugs cannot be applied to biologics. Under current state
laws, pharmacists may substitute conventional generic drugs for namebrands without notifying the physician.”67 The IPA asserts that, “even
with therapeutically interchangeable biologics, underlying differences . . .
may cause adverse events in some patients or may lead individual patients
to respond better to one biologic than another,” and emphasizes the
importance of recordkeeping so that physicians can determine exactly
which biologic was given to the patient.68
According to the Biotechnology Industry Organization (BIO),
states laws that limit substitution “preserve patient access to accurate
prescription information, maintain incentives for innovation, and promote
a competitive market for biologic therapies.”69 The BIO advocates for
“full transparency” in the substitution process as “patients and their
physicians should have the right to know what biologic medicine the
patient receives from the pharmacy.”70 The BIO asserts that state
biosimilar legislation “properly addresses the need for physician
communication and represents the interests of those who stand to benefit
from this new cutting-edge technology.”71
B. Arguments Against State Biosimilar Legislation
In contrast, generic drug manufacturers, third party payers, and
many consumer groups argue that recent state biosimilar substitution
legislation is “designed to preemptively deter the substitution and use of
biosimilars,” which frustrates congressional intent to secure cost savings
for consumers and taxpayers.72 These groups rely on research that shows
66
Mark Lowry, States Grappling With Biosimilar Substitution Laws, Drug Topics: Voice of the Pharmacist,
(Apr. 2, 2015) at http://drugtopics.modernmedicine.com/drug-topics/news/states-grappling-biosimilarsubstitution-laws?page=full.
67
National Conference of State Legislatures, supra, note 54.
68
Id.
69
Id.
70
Id.
71
Id.
72
Purvis, supra note 21.
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“states with patient consent requirements have generic substitution rates
that are 25 percent lower than states that do not.”73 In addition, some
notification provisions effectively stifle competition, since the difficulty in
contacting doctors and the time-consuming recordkeeping will discourage
pharmacists from substituting less-expensive biosimilars for reference
biologics.74 An additional concern among those who oppose state
biosimilar substitution legislation is that requiring pharmacists to inform
patients and obtain the prescriber’s consent to substitute will exacerbate
any lingering anxiety and suspicion of generic alternatives, which will
likely deter biosimilar use.75
Opponents also argue that state biosimilar legislation is “extremely
premature given that the FDA is still in the process of refining the
biosimilar approval pathway, and that implementing state legislation at
such an early stage could result in unnecessary conflict between state and
national laws.”76 Specifically, opponents are concerned that state
legislation could conflict with federal laws that allow substitution for
biosimilars that are considered “interchangeable” with their innovator
counterpart without the involvement of the prescribing doctor. “The FDA
has also expressed concerns about the effects of state biosimilar
substitution legislation on access to lower-cost treatments.”77
According to America's Health Insurance Plans (AHIP), an effort
should be made to “remove barriers at the state level that restrict the use of
biosimilars.”78 AHIP emphasizes that some states have already adopted
legislation that may restrict the availability of biosimilars before they even
reach the market, and expresses concern that these proposals “will limit
patient access to drugs that are not clinically different, yet cost
substantially less than their brand-name counterparts.”79
The Governor of California stated his support for a state bill that
would “allow interchangeable biosimilar drugs to be substituted for
biologic drugs, once approved by the FDA.”80 However, the bill would
have required pharmacists to notify prescribers about which drug was
dispensed.81 The Governor noted that, while doctors may welcome this
73

Id.
Lowry, supra note 58.
Purvis, supra note 21.
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Id.
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Id.
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Richard Cauchi, supra note 5.
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information, there remained a significant concern that the requirement
itself would cast doubt on the safety and desirability of more cost-effective
alternatives to biologics.82
It may come as little surprise that attempts by state legislatures to
erect barriers to generic substitution have been met with firm opposition
from the Generic Pharmaceutical Association (GPhA). The GPhA
maintains that, “Interchangeability or substitution is the engine that drives
generic competition. It is the reason why generic drugs have generated
savings of $1.06 trillion over the past decade. The way that FDA deals
with interchangeability will be directly responsible for the market
dynamics generated by the biosimilar pathway.”83 The GPhA strongly
supports automatic substitution legislation that “allows interchangeable
biologics to be automatically substituted at the pharmacy; upholds the
current pharmacy practice of automatic substitution; insists on the sciencebased FDA determination of interchangeability; and treats all
interchangeables and their corresponding brand biologics the same once an
interchangeable is approved.”84 The GPhA supports legislation that
creates a competitive market for biosimilar products and provides patient
access to affordable versions of these critical medicines.
VI. IMPLICATIONS OF BIOSILIMAR LEGISLATION
State biosimilar legislation will have profound effects on many
aspects of healthcare. There are many rational reasons to support
legislation that preserves the patient-physician relationship, requires
diligent record keeping, and respects a patient’s autonomy in choosing his
or her own treatment plan. However, if states enact legislation that
aggressively discourages substitution, there will be a pronounced reduction
in market competition, and a consequent increase in price. Alternatively,
if states enact legislation that fails to provide sufficient stability in a new
and unpredictable market, pharmaceutical companies will struggle to
realize a return on their investment, which will discourage innovation. If
legislatures fail to protect these investments, innovators will be less likely
to develop new products to treat challenging diseases. The ability of state
legislatures to successfully balance the interests of innovation and access
will have profound impacts on the future sustainability of the
82
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pharmaceutical industry and the provision of healthcare.
A. Effects on the Provision of Healthcare
State legislation will undoubtedly have significant impacts on the
availability and delivery of biologics. Regardless of the challenges that
may exist when selecting a biologic product or a biosimilar counterpart,
there are a number of considerations that should be evaluated by
healthcare providers in order to maximize the value and quality of the
products and service they deliver. Physicians, pharmacists, and all
members of the healthcare team should work together to implement
evidence-based medicine into formulary with the use of approved
biologics and biosimilars in appropriate circumstances.
1. Formulary Management of Biosimilars
While biosimilars may be relatively new, effective formulary
management techniques have been around for decades.85
Most
organizations are familiar with therapeutic interchange protocols for both
traditional and biologic drugs.
The concept, competencies, and
infrastructure already exist for the successful formulary management of
biosimilars.86 Health systems should continue to utilize existing processes
to evaluate biosimilars for formulary inclusion, carefully consider scope of
indications for use, and conduct economic analysis, considering costs,
reimbursement, and patient impact.
Generally, the costs of generic drugs are substantially less than their
brand-name counterparts. The same has yet to be seen with biosimilars
because of limited market competition. “While generic medications
typically cost about 80% less than brand-name drugs, the savings realized
by adding biosimilars to formulary may be less substantial.”87
Biosimilars are expected to cost only about 20 to 30 percent less than the
originator product.88 Although the savings compared to traditional small
molecule drugs are seemingly less significant, biosimilars have the
potential to generate considerable savings and should be thoroughly
85
B. Hawkins, Principles of a Sound Formulary System. Best Practices For Hospital & Health-System
Pharmacy: Positions and Guidance Documents of ASHP. American Society of Health-System Pharmacists;
2006:110-113.
86
Id.
87
Lucio, supra note 11.
88
Id.
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evaluated for formulary inclusion.
2. Pharmacovigilance and Postmarketing Surveillance
Postmarketing surveillance will likely be a major responsibility for
pharmacists and practicing clinicians to identify and report potential safety
and immunogenicity information. Pharmacovigilance activities are
essential to assess the ongoing safety and immunogenicity concerns
associated with the use of biologics. “Because biologic products . . . are
by their very nature capable of eliciting immune responses in humans,
immunogenicity is a focus of safety assessments during development.”89
“The goal of the immunogenicity assessment is to evaluate potential
differences between the biosimilar and the reference product in the
incidence and impact of the human immune response.”90 Post-approval
data collection on safety data for these drugs is important because there is
a limited clinical database at the time of a biosimilar’s approval.91
Another important aspect of post-approval data collection is that the data
allows researchers to distinguish between different biosimilar products and
the reference products, making it possible to ascertain which specific
product a patient has received. “Because of the potential risks associated
with biopharmaceuticals, particularly immunogenicity, and the potential
for clinically meaningful differences between products, there is a need for
rigorous pharmacovigilance programs to monitor all biopharmaceuticals
for safety and efficacy issues during the post-approval period.”92
Manufacturers of biosimilars are required to implement adequate
postmarketing surveillance mechanisms “to differentiate between the
adverse events associated with the proposed product and those associated
with the reference product, including the identification of adverse events
associated with the proposed product that have not been previously
associated with the reference product.” The FDA may also require “a
postmarketing study to evaluate certain safety risks.”93
89
Walter Reinisch, MD & Josef Smolen, MD, Biosimilar Safety Factors in Clinical Practice. 44 Seminars
in Arthritis and Rheumatism, S9, S10 (2015) at http://dij.sagepub.com/content/45/2/155.full.pdf+html.
90
Id. at 12.
91
H. Mellstedt et al., The Challenge of Biosimilars, 19 ANNALS OF ONCOLOGY 411, 415 (2007).
92
Id. at 415-16. Noting, because of the potential risks associated with biopharmaceuticals, particularly
immunogenicity, and the potential for clinically meaningful differences between products, there is a need
for rigorous pharmacovigiliance programs to monitor all biopharmaceuticals for safety and efficacy issues
during the post-approval period.
93
Lisa A. Haile & Kimberly K. Egan, Regulations for Biosimilars. As biologic drug patents begin to expire,
generic versions will hit the market—but how will they be regulated? (June 1, 2012) at http://www.thescientist.com/?articles.view/articleNo/32152/title/Regulations-for-Biosimilars/.
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Pharmacists should leverage their unique position in the healthcare
delivery chain to participate in postmarketing surveillance. Pharmacists
are one of the most accessible healthcare providers for patients to contact
with concerns regarding safety and efficacy of biologics. Furthermore,
pharmacists have access to extensive databases and can utilize existing
systems to ensure adequate recordkeeping and adverse event reporting.
B. Effects on the Pharmaceutical Industry
An additional obstacle for biosimilars involves the particular
manner in which patents are litigated.94 “Biosimilar legislation provides a
highly specific process for the identification and negotiation of patents
between the innovator and the biosimilar applicant.”95 The 351(k)
pathway likely will be the avenue for most biosimilar approvals. The
process requires that a biosimilar sponsor disclose to an innovator critical
information such as its biologics license application and manufacturing
process.96 However litigation challenges could drive competitors to
expedite their entry into the market.97
“Substantial uncertainty remains as to whether biosimilar applicants
would be willing to disclose this information and if the negotiation of
patents can take place within the time frame described by the
legislation.”98 Regulatory uncertainty has increased the level of risk in the
market, which has increased the cost of entry, and resulted in fewer firms
willing to enter the biosimilar market. This is especially problematic for
smaller biotechnology companies whose investments in new biologics
expose them to serious financial risks. If courts and policymakers fail to
protect these investments, innovators will be less likely to develop new
products to treat challenging diseases. Uncertainties over the impending
regulatory framework and defense strategies by name brand biologic
manufacturers have caused delays in biosimilar development.
The FDA should focus on setting guidelines so that more biosimilar
firms can enter the market. There is always a lag between application and
the regulatory decision concerning approval. It is during this time that the
FDA can resolve other issues that have arisen, such as naming and state
substitution laws. It is important for the FDA to establish definitive
94

Preparing for Biosimilars, supra note 16, at 6.
Id.
96
Id.
97
Lucio, supra note 11.
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guidelines to minimize uncertainty so that firms will understand the
process to be undertaken. Only then can biosimilar competition provide
the desired benefit to consumers through access to lower priced alternative
therapies that will allow patients to achieve better medical outcomes.99
Notwithstanding the significant potential for biosimilars, their
establishment in the US market will likely be a slow process. Stringent
clinical requirements and a complicated procedure for resolving patent
disputes are likely to delay market uptake. Originator patents usually have
multiple lines of defense, including process patents, which may also slow
the entry of biosimilars when new markets become available. Given the
highly technical issues involved and the lack legal precedent, it is difficult
to predict how successful the biosimilar market will be in the coming
years.
It will take time for the FDA to believe in the industry’s ability to
safely and consistently reproduce these complex molecules and for
physicians overcome their concerns over safety and efficacy. The
financial motivation for both payers and patients will also be crucial.
However, even if regulatory barriers hinder biosimilars initially, the
financial incentives will ultimately drive acceptance of biosimilar longterm as entry of leading US companies foster the sector’s credibility. A
number of factors will impact the opportunities for cost saving in the US
including ease of access in the short term, speed of uptake, clarity of
regulation and, the role of public and private stakeholders.
The market exclusivity for the top ten best-selling originator
biologics is set to expire between now and 2019, and current estimates
suggest that by 2024, the savings from biosimilars in the US could reach
$250 billion. Despite the lingering concerns regarding the safety and
reproducibility of biosimilars, the market for biosimilars is expected to
experience significant growth in the coming years, being driven by the
extensive pipeline and the number of companies becoming involved in this
area, including some large pharmaceutical companies who are developing
biosimilar versions of competitor products in order to ensure they are able
to compete at all levels.
Some of the most promising biosimilars in the US include Avastin,
Epogen, Herceptin, Humira, Intron A, Neulasta, Neupogen, Pegintron,
Procrit, Remicade, and Rituxin. In July 2014, the FDA accepted a BLA
from Sandoz for (Zarxio) filgrastim, as a biosimilar to the reference
99
Joseph P. Fuhr, Biosimilars Can Save Lives and Cost Less, FORBES (Aug. 8, 2014), available at
http://onforb.es/1ydiWtj.
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biologic Neupogen.100 In August 2014, Celltrion filed a BLA for
infliximab (Remsima) as a biosimilar to the reference biologic
Remicade.101 The FDA recently gave tentative approval to Eli Lilly’s
“biosimilar” insulin glargine (Basaglar), but will not be available until the
company resolves patent litigation with Sanofi.102
The EU has been dealing with biosimilars since 2006. The most
common of which include Omnitrope, Binocrit, Abseamed, Silapo,
Retacrit, TevaGastrim, Ratiogastrim, Biograstim, and Zarzio.103 Although
the EU has established and maintained a seemingly functional system of
approval and regulation for biosimilars, common issues remain to be
resolved regarding substitutability and interchangeability. Given that the
European system has grappled with many of the same issues as the US
concerning substitutability, interchangeability, and nomenclature, it is
apparent that the US is not alone in its struggle to implement a cohesive
system of approval and regulation.

VII. RECOMMENDATIONS
Biosimilars are becoming a significant portion of our national
healthcare spending. Every effort should be made by healthcare
professionals to remain cost conscious, while maintaining a high level of
patient care in all settings. Biosimilars present unique opportunities and
responsibilities for physicians and pharmacists alike. Physicians should
educate themselves about the biologic approval process and remain
mindful that many biosimilars are approved for only a subset of the
indications of its reference biologic. Physicians should work as a part of
the P&T committee, using established evidence-based processes in the
evaluation of medications for formulary consideration. They should
communicate with patients and pharmacists regarding the goals of therapy
and clearly indicate the permissibility of substitution.
Pharmacists should also act as leaders in the objective evaluation of
100
Sandoz Media Center, FDA Accepts Sandoz Application for Biosimilar Filgrastim, (July 24, 2014), at
https://www.novartis.com/news/media-releases/fda-accepts-sandoz-application-biosimilar-filgrastim.
101
Celltrion: What’s New, Celltrion Files for US FDA Approval of Remsima, (Aug. 11, 2014), at
http://www.celltrion.com/en/company/notice_view.asp?idx=456&code=ennews&intNowPage=1&menu_n
um=&align_year=all.
102
Jean-Marc Guettier, MD, Department of Health and Human Services, Tentative Approval, (2014), at
http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/205692Orig1s000TAltr.pdf
103
Generics and Biosimilars Initiative, Biosimilars Approved in Europe, (last updated Feb. 27, 2015), at
http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe.
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biosimilars using existing formulary processes. They should identify
safety and immunogenicity risks and evaluate such risks with respect to
cost containment considerations. Pharmacists should be key players in
pharmacovigilance and leverage their accessibility to patients as well as
their access to databases and existing recordkeeping capabilities as a
conduit of information for government agencies and manufacturers.
Given the complexity of biosimilars, greater scrutiny will be
required of P&T committees than what is traditionally devoted to the
review of generic medications.104 “P&T committees should use a
structured, evidence-based process in the evaluation of medications for
formulary consideration.”105 Brand name products should be when used
only when indicated and pharmacists should utilize substitution for
approved interchangeable products under the same principles of existing
pharmacy law.
Products should only be considered for therapeutic interchange
when there is evidence of therapeutic equivalence, comparable safety
profiles, significant cost advantages, a clear interchange process, an ability
to “opt out” in specific circumstances, and an ability to assess outcomes.106
Although pharmacists can use discretion to substitute interchangeable
products, they are not only allowed, but are expected to utilize generics
absent instructions to the contrary. Decisions should be founded on the
evidence-based clinical, ethical, legal, social, philosophical, quality-of-life,
safety, and economic factors that result in optimal patient care.107
Pharmacists should make a concerted effort to counsel patients on the risks
and benefits of a given biologic product and should proactively
communicate with physicians when substitutions are appropriate.108 The
process of evaluating biosimilars must include physicians, pharmacists,
and other appropriate health care professionals. The process should be
evidence-based and should not be based solely on economic factors.
Regarding payment, insurance companies should be expected to
charge increased rates when patients choose the brand name without
documented medical necessity. Insurance plans will likely use established
formulary-review processes to review each drug on its own merit. If two
drugs are considered “therapeutically equivalent,” then the plan will
104

Lucio, supra note 11.
American Society of Health-System Pharmacists, ASHP Guidelines on the Pharmacy and Therapeutics
Committee and the Formulary System, AM J HEALTH-SYS PHARM, 65:1272–83 (2008).
106
Stevenson, supra note 9.
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decide where on its benefit tier each drug should reside or if it should be
covered at all. Plans are likely to use patient financial incentives to drive
the use of biosimilars. Insurance companies should implement policies
that encourage biosimilar utilization, either through prior-authorization
requirements, or through tiered payment structures that shift a portion of
the cost of the brand name product back to the patient unless the branded
product is considered to be medically necessary by the prescriber.
State laws should recognize that physicians should have the ability
to indicate that a patient is not a candidate for generic substitution or
interchange. While mandatory notice and pre-approval provisions are
unnecessary for interchangeable products, physicians should be able to
prevent substitution when it is determined to be medically necessary.
Pharmacists should only be permitted to make substitutions for products
that are approved as “interchangeable.” Although the pharmacist can play
a key role in patient education, risk management, and adverse event
reporting, the prescribing physician is in the best position to evaluate a
patient’s initial treatment options and must be given a reliable way to
ensure that the patient receives the precise medication that the prescriber
intends. Therefore, even if states do not require pre-authorization,
physicians must be able to mandate the dispensation of the desired product
by writing the phrases “dispense as written” or “brand medically
necessary” on the prescription in order to control the dispensation of a
brand name product when substitution would be inappropriate. However,
as with therapeutic substitutions of traditional small molecule drugs, in the
absence of an indication to the contrary, pharmacists should be expected to
utilize the most cost effective treatment available. If a biologic product has
been approved to be “interchangeable,” it should generally be substituted
unless the prescriber has indicated that such substitution is impermissible.
An effort must be made to reconcile biosimilar substitution laws
with existing state laws on generic substitution. Existing substitutions
laws provide clear and concise rules that enable a physician to prescribe a
medication with knowledge that the pharmacist will attempt to utilize the
most economical treatment for the patient. Physicians are familiar with
the practice of substitution and are provided with various ways to indicate
when substitution is impermissible. In the event that a patient requires a
specific biologic, physicians can use existing practices to indicate when a
particular product should be utilized. State laws should recognize that the
treatment process involves a number of healthcare providers and should
enable each provider to contribute to the safe and effective delivery of
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cost-effective healthcare.
VIII. CONCLUSION
Biosimilars present significant challenges and opportunities for
healthcare providers who manage formularies and develop strategies for
patient care. It is important to engage in a cost-benefit analysis to examine
the true impact on patient welfare. Existing principles of formulary
management that are currently employed for traditional small molecule
drugs should be applied to biosimilars. Pharmacists and other healthcare
providers must educate themselves and be prepared to play leadership
roles in the safe and appropriate introduction of biosimilars into health
systems. Healthcare providers should increase their understanding of the
regulatory pathway for biosimilars, the likely targets for biosimilar
development, and the clinical communications that will need to occur to
support appropriate use.
Federal legislation has successfully implemented a number of cost
saving measures designed reduce overall spending on healthcare without
stifling the development of new medication. State laws should embrace
these cost saving measures and should work alongside federal legislation
to address the concerns of quality and safety without sacrificing dedication
to cost containment. As the market for biologics continues to grow, it will
become increasingly important for state legislation to balance the
competing interests of scientific innovation and public access. With
proper education and the implementation of state laws that support the
optimal utilization of biosimilars, the US system will be one step closer to
affordable healthcare.
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